Call for Abstracts and Proceedings
Authors are invited to submit a one-page abstract. A template will be available online. Abstracts will be accepted only, if the template format is used accurately. Each submission will be peer-reviewed and, if accepted, published in an online open-access proceedings. Each contribution is assigned a DOI.

Additionally, a printed version of the book of abstracts will be available at the symposium.

To be included in the conference publication, a submission of your abstract (latest on Aug 05, 2018) and presentation of your research at the conference (as a talk or poster) is mandatory.

www.gpcr-symposium.de/publication

Scientific Committee

Prof. Dr. med. Gabriela Riemekasten
Director, Department of Rheumatology and Clinical Immunology; Universitätsklinikum Schleswig-Holstein and Universität zu Lübeck

Prof. Dr. med. Yehuda Sheinfeld
Head of the Center of Autoimmunity at Sheba Tel Ha Shomer Hospital, Tel Aviv University, Israel

Univ.-Prof. Dr. med. Fritz Boege
Director, Central Institute for Clinical Chemistry and Laboratory Diagnostics, Universitätssklinikum Düsseldorf

Prof. Dr. med. Duska Dragun
Head of the nephrology research laboratory at the Charité Campus Virchow-Klinikum Berlin

Information

Scientific Chair
Prof. Dr. Gabriela Riemekasten
E-Mail: gabriela.riemekasten@uksh.de

Scientific Office
Dr. Anja Kerstein
E-Mail: anja.kerstein@uksh.de  T: +49 451 500-50866

Host and Organization
Infinite Science GmbH
E-Mail: info@gpcr-symposium.de
T: +49 451 5853-29 01

Venue and Accommodation
Radisson Blu Senator Hotel
Willy-Brandt-Allee 6, 23554 Lübeck, Germany
T: +49 451-14 20 www.senatorhotel.de

The Hotel offers a limited number of rooms at our special rate. Please indicate the key GPCR when booking a room.

Conference Ticket of Deutsche Bahn
Special prices are offered. Further information and online booking: www.infinite-science.de/bahn

Registration
Registration is required for first authors of accepted posters or talks. If you are the first author of an accepted abstract, your registration cannot be refunded. If the first author is unable to attend the meeting and would like to appoint a substitute presenter, contact us by email for final approval. Full payment of the registration fee must be made at the time of registration by credit card (Visa, MasterCard), SofortÜberweisung or within 7 days by bank transfer. Early registration fee needs to be paid by July 15, 2018. Please register online at:

www.gpcr-symposium.de/registration

Registration fee   until 15.07.18 from 16.07.18
Full registration  325 €  375 €
Student registration*  145 €  165 €
Social event  65 €  65 €

* Only valid up to the age of 27 years, student ID required upon registration

Cancellation policy
For cancellations made by Aug 15, 2018, your registration fee will be refunded less a 75 € cancellation fee. No refunds will be given for cancellations made after Aug 15, 2018.

www.gpcr-symposium.de/registration

Disclosure of cooperation:
www.gpcr-symposium.de/transparency

Sponsors

The 2nd Symposium on Functional Autoantibodies Targeting G-Protein-Coupled Receptors is kindly supported by:

EUROIMMUN
a PerkinElmer company

www.gpcr-symposium.de/sponsors

www.gpcr-symposium.de

Call for papers

2nd Symposium on Functional Autoantibodies Targeting G-Protein-Coupled Receptors
September 28 – 30, 2018

12 CME credit points

www.gpcr-symposium.de
Dear Sir or Madam, dear colleagues,

It is a great pleasure to announce the second symposium on functional autoantibodies targeting G-protein-coupled receptors (GPCRs) in Lübeck. GPCRs are involved in a variety of physiological and pathophysiological processes. So far, much effort has been made on anti-GPCR drug discovery with a focus on the development of small molecules and monoclonal antibodies for the treatment of cancer, infection, metabolic disorders or inflammatory diseases. Recently, functional autoantibodies directed against GPCRs were identified in various diseases associated with pathogenesis, uncovering a potential new field of therapeutic intervention. Thus, the aim of this symposium is to combine the current knowledge on the role of GPCRs in different pathologies, their mode of action and state-of-the-art research techniques to identify common fundamental pathways that can be transferred to other disease entities with similar manifestations.

I cordially invite you to participate in this inspiring symposium with outstanding speakers from the field of GPCR research and constructive discussions as well as poster sessions. I look forward to welcome you to the beautiful Hanseatic City of Lübeck and encourage you and your colleagues to contribute to this exciting meeting.

Prof. Dr. med. Gabriela Riemekasten
Director
Department of Rheumatology and Clinical Immunology
Universitätsklinikum Schleswig-Holstein
Universität zu Lübeck

---

### Program

**Friday, September 28, 2018**

**16:00 - 20:00**

Registration

**17:00 - 18:30**

Welcome and opening lectures

- Welcome note by the University President
  Gabrielle Glesser-Kaesbach
- Welcome note by the Symposium’s Chair
  Gabriela Riemekasten
- Challenges in the research of anti-GPCR ab I
  Duska Dragun
- Challenges in the research of anti-GPCR ab II
  Martin Lobnig

**18:40 - 20:30**

Get-together

**Saturday, September 29, 2018**

**09:00 - 10:30**

Anti-GPCR ab: advantages, pitfalls and problems in the diagnosis

Functional ab causing psychiatric manifestations:
- Lessons need to be learned
  Yehuda Shoenfeld
- Ab signatures in autoimmune and non-autoimmune diseases
  Gabriela Riemekasten
- Lessons from TSRH ab: pitfalls and challenges in their diagnostic
  Simon Lytton

**10:30 - 11:00**

Coffee break

**11:00 - 12:30**

Are Anti-GPCR ab pathogenic?

- β-adrenergic receptor ab: pitfalls in the diagnostic and in studying ab effects
  Fritz Boege
- Novel targets in the diagnosis of autoimmune and non-autoimmune diseases
  Harald Heidecke
- Anti-AT1R ab and autoimmunity to GPCR as cause or contributor to skin fibrosis and interstitial lung disease
  Xinhua Yu
- Monoclonal anti-AT1R ab from a SSc mouse model: evaluation of their functions
  Frank Petersen

**12:30 - 13:30**

Lunch break

**13:30 - 14:30**

Poster session

**14:30 - 16:00**

Signaling of anti-GPCR ab: can we identify novel targets?

- Signaling and GPCR biology using cell models
  Aurelie Philippe
- Lessons from dermatology: Anti-Dsg1/3 und anti-BP180-induced signaling
  Ralf Ludwig
- Role of antibodies against PAR-1 and PAR 2 in different diseases
  Rusan Catar

**16:00 - 16:30**

Coffee break

**16:30 - 18:00**

Anti-GPCR ab as marker for diseases and therapeutic responses

- Antibodies against complement receptors: impact on pathophysiology
  Christian Kanster
- Anti-GPCR ab in attherosclerosis
  Zsuhas Anedrhu
- Immunoadsorption in Vascular Dementia - a novel approach to Alzheimer’s Disease?
  Hans Grabe

First results of the prospective ETICS-Study: inflammation rather than ischemia triggers the development of cardiac GPCR-autoantibodies

Roland Jahn
Talks from selected abstracts

---

**Sunday, September 30, 2018**

**09:00 - 10:30**

The difficulty of applying new treatment options in outpatient and clinical patient care.

- Chronic Fatigue-Syndrom und Apherese
  Carmen Schreiberbogen
- The DNA-based therapeutic agent BC 007 completely neutralizes agonistic autoantibodies directed against 1-adrenoreceptors: results of a phase 1 trial
  Niels-Peter Becker

Talks from selected abstracts

**10:30 - 11:00**

Coffee break

**11:00 - 12:15**

Summary and round table discussion, closing remarks

- 30 years of functional anti-GPCR ab: how to come into the clinical practice? What is missing to convince others?
  Gabriela Riemekasten

Closing remarks

---

**Registration**

- **16:00 - 20:00**
  - Welcome and opening lectures
  - Get-together

---

**Themes**

- Anti-GPCR ab: advantages, pitfalls and problems in the diagnosis
- Functional ab causing psychiatric manifestations
- Lessons need to be learned
- Ab signatures in autoimmune and non-autoimmune diseases
- Lessons from TSRH ab: pitfalls and challenges in their diagnostic
- Coffee break
- Are Anti-GPCR ab pathogenic?
- β-adrenergic receptor ab: pitfalls in the diagnostic and in studying ab effects
- Novel targets in the diagnosis of autoimmune and non-autoimmune diseases
- Anti-AT1R ab and autoimmunity to GPCR as cause or contributor to skin fibrosis and interstitial lung disease
- Monoclonal anti-AT1R ab from a SSc mouse model: evaluation of their functions
- Lunch break
- Poster session
- Signaling of anti-GPCR ab: can we identify novel targets?
- Signaling and GPCR biology using cell models
- Lessons from dermatology: Anti-Dsg1/3 und anti-BP180-induced signaling
- Role of antibodies against PAR-1 and PAR 2 in different diseases
- Coffee break
- Anti-GPCR ab as marker for diseases and therapeutic responses
- Antibodies against complement receptors: impact on pathophysiology
- Anti-GPCR ab in attherosclerosis
- Immunoadsorption in Vascular Dementia - a novel approach to Alzheimer’s Disease?
- First results of the prospective ETICS-Study: inflammation rather than ischemia triggers the development of cardiac GPCR-autoantibodies
- Talks from selected abstracts
- Summary and round table discussion, closing remarks
- 30 years of functional anti-GPCR ab: how to come into the clinical practice? What is missing to convince others?
- Closing remarks